8 recruiting, 3 active not recruiting, 3 terminated, 2 completed. 13 Phase 1, 7 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Recruiting 6, Active not recruiting 2, Completed 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 7 | Recruiting 3, Active not recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Pheresis: new trials by email Literature Review of Pheresis trials Research Report on Pheresis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography - Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 30 | 2025-05-21 | 2026-05-08 |
| FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia FOLR1 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 12 | 2025-02-24 | 2026-08-06 |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 216 | 2024-07-09 | 2026-10-23 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 9 | 2023-06-02 | 2026-10-01 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer Atezolizumab, Bevacizumab, External Beam Radiation Therapy - Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 85 | 2019-09-19 | 2026-10-05 |
| Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim - Plasma Cell Leukemia in Remission, Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2018-01-01 | 2017-12-13 | |
| Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma Cryosurgery, Pembrolizumab, Pheresis - Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 7 | 2017-11-15 | 2025-06-12 |
| Dendritic Cell Vaccine for Children and Adults With Sarcoma Dendritic Cells Vaccine, Lysate of Tumor, Gemcitabine - Sarcoma, Soft Tissue Sarcoma | Phase 1 | Completed | Macarena De La Fuente, MD | 19 | 2014-01-06 | 2024-07-03 |
| Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Dendritic Cell Vaccine, Tumor Lysate, Imiquimod - Glioma, Brain Cancer | Phase 1 | Terminated | Edward Ziga | 1 | 2013-09-03 | 2017-03-10 |
| Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma Dendritic Cell Vaccine, Tumor Lysate, Imiquimod - Malignant Glioma, Glioblastoma Multiforme | Phase 1 | Completed | Macarena De La Fuente, MD | 20 | 2013-08-21 | 2022-07-20 |
| Alloantibodies in Pediatric Heart Transplantation Induction Therapy, Tacrolimus, Mycophenolate Mofetil - Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 290 | 2010-01-01 | 2017-04-20 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Non-Hodgkin (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Glioma (3) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Glioblastoma (2) · Hodgkin Disease (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Multiple Myeloma (2) · Myeloproliferative Disorders (2) · Primary Myelofibrosis (2) · Astrocytoma (1) · Blast Crisis (1) · Bone Neoplasms (1)
City of Hope Medical Center (4) · Mayo Clinic (3) · Fred Hutchinson Cancer Center (2) · Macarena De La Fuente, MD (2) · Ohio State University Comprehensive Cancer Center (2) · Edward Ziga (1) · Emory University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Sumithira Vasu (1)
United States (17) · Canada (1)
Sumithira Vasu, MD (2) · Edward Ziga, MD (1) · George Somlo, MD (1) · Gina D'Amato, MD (1) · James B Elder, MD (1) · Joseph Rimando, MD (1) · Katherine G. Tarlock, MD (1) · Lewis R. Roberts, MD, PhD (1) · Lionel Kankeu Fonkoua, MD (1) · Macarena De La Fuente, MD (1) · Matthew S. Block, M.D., Ph.D. (1) · Matthew S. Block, MD, PhD (1) · Naveed Ali, MD (1) · Ryotaro Nakamura (1) · Stephen A. Webber, MBChB, MRCP (1)
PMID 31324444, PMID 35115306, PMID 40873341, PMID 42500906
P30CA033572 (3), P30CA138292 (1), R01CA266783 (1), R01CA274985 (1), R01CA276313 (1), R01CA276374 (1), R01CA294704 (1), U01AI077867 (1)